Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1985 4
1989 1
2005 4
2006 3
2007 2
2008 5
2009 2
2010 6
2011 9
2012 10
2013 3
2014 8
2015 4
2016 6
2017 7
2018 5
2019 5
2020 7
2021 3
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. McCubrey JA, et al. Among authors: abrams sl. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. doi: 10.1016/j.bbamcr.2006.10.001. Epub 2006 Oct 7. Biochim Biophys Acta. 2007. PMID: 17126425 Free PMC article. Review.
Emerging MEK inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: abrams sl. Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23. doi: 10.1517/14728210903282760. Expert Opin Emerg Drugs. 2010. PMID: 20151845 Review.
Cancer therapy and treatments during COVID-19 era.
Akula SM, Abrams SL, Steelman LS, Candido S, Libra M, Lerpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Blalock WL, Piazzi M, Montalto G, Cervello M, Notarbartolo M, Basecke J, McCubrey JA. Akula SM, et al. Among authors: abrams sl. Adv Biol Regul. 2020 Aug;77:100739. doi: 10.1016/j.jbior.2020.100739. Epub 2020 Jun 26. Adv Biol Regul. 2020. PMID: 32773105 Free PMC article. Review.
Emerging Raf inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: abrams sl. Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Expert Opin Emerg Drugs. 2009. PMID: 19715444 Review.
Advances in targeting signal transduction pathways.
McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN. McCubrey JA, et al. Among authors: abrams sl. Oncotarget. 2012 Dec;3(12):1505-21. doi: 10.18632/oncotarget.802. Oncotarget. 2012. PMID: 23455493 Free PMC article. Review.
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer.
Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L, Ratti S, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D, McCubrey JA. Duda P, et al. Among authors: abrams sl. Cells. 2020 Apr 30;9(5):1110. doi: 10.3390/cells9051110. Cells. 2020. PMID: 32365809 Free PMC article. Review.
GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells.
Duda P, Akula SM, Abrams SL, Steelman LS, Gizak A, Rakus D, McCubrey JA. Duda P, et al. Among authors: abrams sl. Biochim Biophys Acta Mol Cell Res. 2020 Oct;1867(10):118770. doi: 10.1016/j.bbamcr.2020.118770. Epub 2020 Jun 7. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 32524999 Free article. Review.
The therapeutic potential of mTOR inhibitors in breast cancer.
Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA. Steelman LS, et al. Among authors: abrams sl. Br J Clin Pharmacol. 2016 Nov;82(5):1189-1212. doi: 10.1111/bcp.12958. Epub 2016 May 10. Br J Clin Pharmacol. 2016. PMID: 27059645 Free PMC article. Review.
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling.
Steelman LS, Chappell WH, Akula SM, Abrams SL, Cocco L, Manzoli L, Ratti S, Martelli AM, Montalto G, Cervello M, Libra M, Candido S, McCubrey JA. Steelman LS, et al. Among authors: abrams sl. Adv Biol Regul. 2020 Dec;78:100758. doi: 10.1016/j.jbior.2020.100758. Epub 2020 Sep 28. Adv Biol Regul. 2020. PMID: 33022466 Review.
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: abrams sl. Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494257 Review.
87 results